1624\$

PATENTS

DEC 0 4 2003



IN THE UNITED STRATES PATENT AND TRADMARK OFFICE

Applicant: Schrimpf, et al.

Serial No.: 09/833,914

Filed: April 12, 2001

For: DIAZABICYCLIC CENTRAL

NERVOUS SYSTEM ACTIVE

AGENTS

Examiner: B. L. Coleman

Group Art Unit: 1624

Case No.: 6696.US.O2

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 CERTIFICATE OF MAILING (37 C.F.R. § 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 on:

Date of Deposit: November 19, 2003

to un Que al Wh

nya Parent Da

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS are the following:

- 1. Response to Advisory Action (9 Pages);
- 2. Request for Two-Month Extension of Time, in duplicate; and
- 3. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Schrimpf, et al.

Customer No. 23492

Telephone: (847) 937-8272

Facsimile: (847) 938-2623

ABBOTT LABORATORIES

Rortia Chen

Registration No. 44,075 Attorney for Applicants

Respectfully submitted,